13F Holdings
中文EN

RVMD Revolution Medicines, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1628171 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-94.6%
TTM EPS YoY-75.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-93.6%
ROA-57.1%
ROIC (approx.)-84.1%
Asset turnover—

Leverage & solvency

Liabilities / assets44.2%
Debt / equity0.00x
Current ratio8.36x
Interest coverage-20.62x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-13.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0$11.58M$35.38M$29.39M
R&D expense$987.33M$592.23M$423.14M$253.07M$186.95M
SG&A expense$195.04M$97.30M$75.62M$40.59M$30.45M
Operating income-$1.18B-$689.52M-$487.19M-$258.28M-$188.01M
Interest expense$24.23M$0$0$0$12,000
Pretax income-$1.13B-$600.85M-$439.89M-$249.12M-$187.09M
Income tax$0-$753,000-$3.52M-$420,000$0
Net income-$1.13B-$600.09M-$436.37M-$248.71M-$187.09M
EBITDA-$1.17B-$682.97M-$482.14M-$254.31M-$184.91M
EPS (basic)-5.95-3.58-3.86-3.08-2.57
EPS (diluted)-5.95-3.58-3.86-3.08-2.57
Weighted avg. shares (diluted)190.13M167.74M113.15M80.63M72.81M
Balance sheet
Cash & equivalents$383.75M$543.06M$696.15M$161.41M$108.50M
Short-term investments$1.64B$1.75B$1.16B$483.53M$468.56M
Receivables$0————
Inventory$0————
Current assets$2.08B$2.33B$1.88B$660.18M$589.77M
PP&E, net$33.19M$24.29M$22.86M$18.66M$11.54M
Goodwill$14.61M$14.61M$14.61M$14.61M$14.61M
Intangibles$55.80M$56.67M$57.74M$58.81M$59.88M
Total assets$2.35B$2.56B$2.06B$811.93M$737.99M
Current liabilities$290.42M$163.91M$143.85M$61.98M$60.35M
Total liabilities$723.21M$293.10M$235.51M$126.74M$135.42M
Shareholders' equity$1.63B$2.27B$1.83B$685.19M$602.57M
Shares outstanding197.00M185.90M164.67M90.41M74.14M
Cash flow statement
Operating cash flow-$897.74M-$557.44M-$350.57M-$224.40M-$147.18M
Capital expenditure$15.99M$10.31M$7.73M$10.82M$6.53M
Free cash flow-$913.73M-$567.74M-$358.30M-$235.22M-$153.71M
Investing cash flow$118.06M-$554.39M-$342.60M-$24.12M-$142.12M
Financing cash flow$621.52M$959.41M$1.23B$301.43M$294.18M
Depreciation & amortization$7.78M$6.56M$5.04M$3.97M$3.10M
Stock-based compensation$118.39M$79.20M$61.77M$31.20M$20.72M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.